| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| CSTLCastle Biosciences, Inc. | 1.19B | 40.75 | 65.73 | 51.09% | -3.56% | -2.62% | 3.07% | 0.06 |
| MYNZMainz Biomed B.V. | 10.78M | 1.19 | -0.05 | -0.17% | -24.92% | -6.63% | 0.54 | |
| BNRBurning Rock Biotech Limited | 301.02M | 33.32 | -0.99 | -4.02% | -22.48% | -22.06% | 0.09 | |
| MDXHMDxHealth S.A. | 190.56M | 3.71 | -3.20 | 28.29% | -40.43% | -345.31% | 4.05 | |
| PSNLPersonalis, Inc. | 853.41M | 9.61 | -7.01 | 15.15% | -106.92% | -43.1% | 0.22 | |
| EXASExact Sciences Corporation | 19.44B | 102.34 | -18.31 | 10.37% | -32.01% | -39.44% | 0.38% | 1.15 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 39.44M | 99.38M | 265.99M | 454.46M | 876.29M | 1.49B | 1.77B | 2.08B | 2.5B | 2.76B |
| Revenue Growth % | 20.93% | 1.52% | 1.68% | 0.71% | 0.93% | 0.7% | 0.18% | 0.18% | 0.2% | 0.1% |
| Cost of Goods Sold | 24.5M | 45.2M | 79.2M | 117.98M | 216.72M | 354.3M | 458.76M | 661.36M | 737.6M | 840.2M |
| COGS % of Revenue | 0.62% | 0.45% | 0.3% | 0.26% | 0.25% | 0.24% | 0.26% | 0.32% | 0.3% | 0.3% |
| Gross Profit | 14.94M | 54.18M | 186.79M | 336.48M | 659.58M | 1.14B | 1.31B | 1.42B | 1.76B | 1.92B |
| Gross Margin % | 0.38% | 0.55% | 0.7% | 0.74% | 0.75% | 0.76% | 0.74% | 0.68% | 0.7% | 0.7% |
| Gross Profit Growth % | 6.91% | 2.63% | 2.45% | 0.8% | 0.96% | 0.72% | 0.15% | 0.09% | 0.24% | 0.09% |
| Operating Expenses | 174M | 223.2M | 305.1M | 495.95M | 893.36M | 1.9B | 2.16B | 2.02B | 1.98B | 2.97B |
| OpEx % of Revenue | 4.41% | 2.25% | 1.15% | 1.09% | 1.02% | 1.28% | 1.22% | 0.97% | 0.79% | 1.08% |
| Selling, General & Admin | 140.09M | 189.72M | 262.96M | 427.74M | 737.63M | 1.07B | 1.66B | 1.59B | 1.62B | 1.67B |
| SG&A % of Revenue | 3.55% | 1.91% | 0.99% | 0.94% | 0.84% | 0.72% | 0.94% | 0.76% | 0.65% | 0.6% |
| Research & Development | 33.91M | 33.47M | 42.14M | 68.21M | 139.69M | 554.05M | 385.65M | 394.19M | 426.93M | 431.21M |
| R&D % of Revenue | 0.86% | 0.34% | 0.16% | 0.15% | 0.16% | 0.37% | 0.22% | 0.19% | 0.17% | 0.16% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 16.04M | 279.42M | 115.21M | 29.21M | -70.05M | 868.06M |
| Operating Income | -159.07M | -169.02M | -118.31M | -159.47M | -233.78M | -767.7M | -855.68M | -593.51M | -215.01M | -1.05B |
| Operating Margin % | -4.03% | -1.7% | -0.44% | -0.35% | -0.27% | -0.51% | -0.48% | -0.28% | -0.09% | -0.38% |
| Operating Income Growth % | -0.58% | -0.06% | 0.3% | -0.35% | -0.47% | -2.28% | -0.11% | 0.31% | 0.64% | -3.88% |
| EBITDA | -151.32M | -157.51M | -102.75M | -136.39M | -183.53M | -604.33M | -675.33M | -395.95M | -8.4M | -833.84M |
| EBITDA Margin % | -3.84% | -1.58% | -0.39% | -0.3% | -0.21% | -0.41% | -0.38% | -0.19% | -0% | -0.3% |
| EBITDA Growth % | -0.56% | -0.04% | 0.35% | -0.33% | -0.35% | -2.29% | -0.12% | 0.41% | 0.98% | -98.22% |
| D&A (Non-Cash Add-back) | 7.75M | 11.51M | 15.55M | 23.08M | 50.25M | 163.36M | 180.35M | 197.56M | 206.61M | 214.86M |
| EBIT | -157.8M | -167M | -114.38M | -140.54M | -397.71M | -817.24M | -829.63M | -618.66M | -177.32M | -1B |
| Net Interest Income | -6K | -213K | -206K | -36.79M | -27.27M | -10.55M | -12.88M | -13.91M | -24.42M | -31.97M |
| Interest Income | 0 | 0 | 0 | 0 | 23.77M | 6.57M | 0 | 0 | 0 | 0 |
| Interest Expense | 6K | 213K | 206K | 36.79M | 51.04M | 17.12M | 12.88M | 13.91M | 24.42M | 31.97M |
| Other Income/Expense | 1.26M | 1.8M | 3.73M | -15.59M | -172.66M | -61.37M | 13.17M | -39.06M | 13.27M | 12.54M |
| Pretax Income | -157.8M | -167.21M | -114.58M | -175.06M | -406.44M | -829.06M | -842.51M | -632.57M | -201.75M | -1.04B |
| Pretax Margin % | -4% | -1.68% | -0.43% | -0.39% | -0.46% | -0.56% | -0.48% | -0.3% | -0.08% | -0.38% |
| Income Tax | 0 | 0 | -187K | 92K | -193.35M | -5.46M | -246.88M | -9.06M | 2.4M | -7.3M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 0.52% | 0.99% | 0.71% | 0.99% | 1.01% | 0.99% |
| Net Income | -157.8M | -167.21M | -114.4M | -175.15M | -213.09M | -823.61M | -595.63M | -623.51M | -204.15M | -1.03B |
| Net Margin % | -4% | -1.68% | -0.43% | -0.39% | -0.24% | -0.55% | -0.34% | -0.3% | -0.08% | -0.37% |
| Net Income Growth % | -0.58% | -0.06% | 0.32% | -0.53% | -0.22% | -2.87% | 0.28% | -0.05% | 0.67% | -4.04% |
| Net Income (Continuing) | -157.8M | -167.21M | -114.4M | -175.15M | -213.09M | -823.61M | -595.63M | -623.51M | -204.15M | -1.03B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.71 | -1.63 | -0.99 | -1.43 | -1.62 | -5.45 | -3.48 | -3.54 | -1.13 | -5.59 |
| EPS Growth % | -0.37% | 0.05% | 0.39% | -0.44% | -0.13% | -2.36% | 0.36% | -0.02% | 0.68% | -3.95% |
| EPS (Basic) | -1.71 | -1.63 | -0.99 | -1.43 | -1.62 | -5.45 | -3.48 | -3.54 | -1.13 | -5.59 |
| Diluted Shares Outstanding | 92.14M | 102.33M | 115.68M | 122.21M | 131.26M | 151.14M | 171.35M | 176.35M | 180.14M | 184.2M |
| Basic Shares Outstanding | 92.14M | 102.33M | 115.68M | 122.21M | 131.26M | 151.14M | 171.35M | 176.35M | 180.14M | 184.2M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 325.86M | 333.57M | 487.22M | 1.23B | 553.94M | 2.2B | 1.43B | 982.26M | 1.19B | 1.57B |
| Cash & Short-Term Investments | 306.88M | 311.1M | 424.71M | 1.12B | 323.65M | 1.84B | 1.03B | 632.06M | 777.64M | 1.04B |
| Cash Only | 41.13M | 48.92M | 77.49M | 160.43M | 177.25M | 1.49B | 315.47M | 242.49M | 605.38M | 600.89M |
| Short-Term Investments | 265.74M | 262.18M | 347.22M | 963.75M | 146.4M | 348.7M | 715M | 389.56M | 172.27M | 437.14M |
| Accounts Receivable | 4.93M | 8.53M | 26.42M | 45.33M | 130.36M | 233.19M | 216.65M | 158.04M | 203.62M | 248.97M |
| Days Sales Outstanding | 45.66 | 31.32 | 36.25 | 36.41 | 54.3 | 57.07 | 44.75 | 27.68 | 29.73 | 32.94 |
| Inventory | 6.68M | 6.83M | 26.03M | 39.15M | 61.72M | 92.27M | 104.99M | 118.26M | 127.47M | 162.38M |
| Days Inventory Outstanding | 99.47 | 55.18 | 119.95 | 121.11 | 103.96 | 95.05 | 83.54 | 65.27 | 63.08 | 70.54 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 73.9M | 85.63M | 122.05M |
| Total Non-Current Assets | 38.17M | 43.47M | 111.34M | 295.95M | 2.95B | 2.73B | 5.26B | 5.24B | 5.28B | 4.36B |
| Property, Plant & Equipment | 34.1M | 38.14M | 79.99M | 245.26M | 581.77M | 577.93M | 754.47M | 851.76M | 842.06M | 810.63M |
| Fixed Asset Turnover | 1.16x | 2.61x | 3.33x | 1.85x | 1.51x | 2.58x | 2.34x | 2.45x | 2.97x | 3.40x |
| Goodwill | 0 | 0 | 1.98M | 17.28M | 1.2B | 1.24B | 2.34B | 2.35B | 2.37B | 2.37B |
| Intangible Assets | 0 | 1.55M | 22.23M | 29M | 1.14B | 847.12M | 2.09B | 1.96B | 1.89B | 1.01B |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 4.07M | 3.77M | 7.15M | 4.42M | 23.32M | 63.77M | 74.59M | 90.58M | 177.39M | 169.72M |
| Total Assets | 364.3M | 377.04M | 598.56M | 1.52B | 3.51B | 4.93B | 6.68B | 6.23B | 6.47B | 5.93B |
| Asset Turnover | 0.11x | 0.26x | 0.44x | 0.30x | 0.25x | 0.30x | 0.26x | 0.33x | 0.39x | 0.47x |
| Asset Growth % | 0.17% | 0.03% | 0.59% | 1.55% | 1.3% | 0.4% | 0.36% | -0.07% | 0.04% | -0.08% |
| Total Current Liabilities | 26.72M | 30.69M | 68.12M | 136.59M | 236.49M | 633.1M | 517.07M | 412.75M | 514.7M | 732.19M |
| Accounts Payable | 3.31M | 710K | 16.14M | 28.14M | 25.97M | 35.71M | 67.83M | 74.92M | 78.82M | 89.57M |
| Days Payables Outstanding | 49.28 | 5.73 | 74.36 | 87.06 | 43.74 | 36.79 | 53.97 | 41.35 | 39 | 38.91 |
| Short-Term Debt | 166K | 174K | 182K | 8K | 834K | 314.03M | 0 | 0 | 50M | 249.15M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 9.46M | 18.26M | 29.08M | 44.51M | 103.63M | 162.92M | 214.49M | 211.5M | 262.44M | 223.7M |
| Current Ratio | 12.19x | 10.87x | 7.15x | 8.99x | 2.34x | 3.47x | 2.76x | 2.38x | 2.32x | 2.15x |
| Quick Ratio | 11.94x | 10.65x | 6.77x | 8.70x | 2.08x | 3.33x | 2.56x | 2.09x | 2.07x | 1.92x |
| Cash Conversion Cycle | 95.85 | 80.77 | 81.84 | 70.46 | 114.51 | 115.33 | 74.32 | 51.6 | 53.81 | 64.57 |
| Total Non-Current Liabilities | 10.45M | 11.05M | 10.02M | 706.91M | 981.21M | 2.06B | 2.78B | 2.77B | 2.81B | 2.79B |
| Long-Term Debt | 4.79M | 4.63M | 4.27M | 689.24M | 827.64M | 1.88B | 2.18B | 2.24B | 2.31B | 2.32B |
| Capital Lease Obligations | 1.06M | 686K | 0 | 0 | 118.67M | 121.08M | 182.17M | 182.4M | 161.07M | 157.13M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4.6M | 5.73M | 5.75M | 17.67M | 34.91M | 51.34M | 417.78M | 352.46M | 335.98M | 315.5M |
| Total Liabilities | 37.44M | 41.74M | 78.14M | 843.08M | 1.22B | 2.69B | 3.3B | 3.18B | 3.33B | 3.53B |
| Total Debt | 6.02M | 5.49M | 4.45M | 689.25M | 955.03M | 2.33B | 2.38B | 2.45B | 2.55B | 2.75B |
| Net Debt | -35.12M | -43.43M | -73.04M | 528.82M | 777.77M | 839.33M | 2.07B | 2.2B | 1.95B | 2.15B |
| Debt / Equity | 0.02x | 0.02x | 0.01x | 1.01x | 0.42x | 1.04x | 0.70x | 0.80x | 0.81x | 1.15x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -26511.33x | -793.50x | -574.32x | -4.33x | -4.58x | -44.84x | -66.44x | -42.68x | -8.80x | -32.80x |
| Total Equity | 326.86M | 335.3M | 520.42M | 680.94M | 2.29B | 2.24B | 3.39B | 3.04B | 3.15B | 2.4B |
| Equity Growth % | 0.13% | 0.03% | 0.55% | 0.31% | 2.36% | -0.02% | 0.52% | -0.1% | 0.03% | -0.24% |
| Book Value per Share | 3.55 | 3.28 | 4.50 | 5.57 | 17.43 | 14.79 | 19.77 | 17.26 | 17.46 | 13.04 |
| Total Shareholders' Equity | 326.86M | 335.3M | 520.42M | 680.94M | 2.29B | 2.24B | 3.39B | 3.04B | 3.15B | 2.4B |
| Common Stock | 968K | 1.1M | 1.21M | 1.23M | 1.48M | 1.59M | 1.74M | 1.78M | 1.81M | 1.86M |
| Retained Earnings | -578.61M | -745.82M | -860.61M | -1.04B | -1.12B | -2.05B | -2.64B | -3.27B | -3.47B | -4.5B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -433K | -418K | -750K | -1.42M | -100K | 526K | -1.44M | -5.24M | 1.43M | -944K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -134.02M | -130.07M | -71.72M | -69.33M | -111.66M | 136.48M | -102.24M | -223.56M | 156.12M | 210.54M |
| Operating CF Margin % | -3.4% | -1.31% | -0.27% | -0.15% | -0.13% | 0.09% | -0.06% | -0.11% | 0.06% | 0.08% |
| Operating CF Growth % | -0.66% | 0.03% | 0.45% | 0.03% | -0.61% | 2.22% | -1.75% | -1.19% | 1.7% | 0.35% |
| Net Income | -157.8M | -167.21M | -114.4M | -175.15M | -213.09M | -848.53M | -595.63M | -623.51M | -204.15M | -1.03B |
| Depreciation & Amortization | 7.75M | 11.51M | 15.55M | 23.08M | 50.25M | 163.36M | 180.35M | 197.56M | 206.61M | 214.86M |
| Stock-Based Compensation | 18.05M | 23.73M | 35.51M | 60.26M | 108.48M | 152.91M | 253.06M | 206.82M | 231.31M | 214.88M |
| Deferred Taxes | 363K | 800K | -115K | -2.78M | -193.6M | -9.86M | -253.17M | -11.9M | -955K | -10.12M |
| Other Non-Cash Items | -529K | -347K | -601K | 26.17M | 189.87M | 721.34M | 202.04M | 33.84M | -76.36M | 875.78M |
| Working Capital Changes | -1.85M | 1.45M | -7.68M | -911K | -53.56M | -42.73M | 111.11M | -26.38M | -342K | -56.01M |
| Change in Receivables | -3.56M | -3.59M | -17.53M | -17.29M | -27.63M | -100.53M | 25.15M | 61.09M | -43.42M | -46.26M |
| Change in Inventory | -2.66M | -156K | -19.19M | -12.73M | -19.04M | -30.31M | -9.22M | -13.23M | -7.69M | -34.91M |
| Change in Payables | 661K | -2.6M | 15.38M | 11.33M | 0 | 46.38M | 0 | 0 | 0 | 43.54M |
| Cash from Investing | -64.75M | -11.52M | -160.81M | -781.91M | -124.43M | -702.04M | -1.08B | 74.07M | 49.68M | -442.15M |
| Capital Expenditures | -21.98M | -14.85M | -69.24M | -150.67M | -172.65M | -64.35M | -135.77M | -214.46M | -124.19M | -135.99M |
| CapEx % of Revenue | 0.56% | 0.15% | 0.26% | 0.33% | 0.2% | 0.04% | 0.08% | 0.1% | 0.05% | 0.05% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.9M | -230K | -109.34M | -614.3M | -1M | -411.8M | -58.82M | 24.45M | -250K | -225K |
| Cash from Financing | 181.76M | 149.59M | 260.96M | 934.14M | 253.18M | 1.88B | 8.47M | 76.48M | 159.77M | 231.87M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 2.97M | 5.51M | 7.94M | 13.48M | 17.06M | 43.68M | 32.22M | 26.48M | 21.79M | -17.75M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -156M | -144.92M | -140.96M | -220M | -284.31M | 72.13M | -238M | -438.02M | 31.93M | 74.55M |
| FCF Margin % | -3.96% | -1.46% | -0.53% | -0.48% | -0.32% | 0.05% | -0.13% | -0.21% | 0.01% | 0.03% |
| FCF Growth % | -0.67% | 0.07% | 0.03% | -0.56% | -0.29% | 1.25% | -4.3% | -0.84% | 1.07% | 1.33% |
| FCF per Share | -1.69 | -1.42 | -1.22 | -1.80 | -2.17 | 0.48 | -1.39 | -2.48 | 0.18 | 0.40 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.78x | 0.63x | 0.40x | 0.52x | -0.17x | 0.17x | 0.36x | -0.76x | -0.20x |
| Interest Paid | 0 | 0 | 0 | 0 | 5.13M | 0 | 10.73M | 11.52M | 18.78M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -51.25% | -50.51% | -26.74% | -29.16% | -14.35% | -36.41% | -21.18% | -19.39% | -6.6% | -37.09% |
| Return on Invested Capital (ROIC) | -45.32% | -43.44% | -24.01% | -14.43% | -8.2% | -18.75% | -15.05% | -8.32% | -3.12% | -16.3% |
| Gross Margin | 37.87% | 54.52% | 70.23% | 74.04% | 75.27% | 76.24% | 74.04% | 68.27% | 70.49% | 69.55% |
| Net Margin | -400.14% | -168.26% | -43.01% | -38.54% | -24.32% | -55.22% | -33.71% | -29.91% | -8.17% | -37.29% |
| Debt / Equity | 0.02x | 0.02x | 0.01x | 1.01x | 0.42x | 1.04x | 0.70x | 0.80x | 0.81x | 1.15x |
| Interest Coverage | -26511.33x | -793.50x | -574.32x | -4.33x | -4.58x | -44.84x | -66.44x | -42.68x | -8.80x | -32.80x |
| FCF Conversion | 0.85x | 0.78x | 0.63x | 0.40x | 0.52x | -0.17x | 0.17x | 0.36x | -0.76x | -0.20x |
| Revenue Growth | 2093.38% | 151.99% | 167.66% | 70.86% | 92.82% | 70.19% | 18.49% | 17.95% | 19.93% | 10.37% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Screening | - | - | - | - | - | 1.86B | 2.1B |
| Screening Growth | - | - | - | - | - | - | 12.83% |
| Precision Oncology | - | - | - | - | - | 629.11M | 655M |
| Precision Oncology Growth | - | - | - | - | - | - | 4.12% |
| COVID-19 Testing | - | - | 235.83M | 143.1M | 58.09M | 5.96M | - |
| COVID-19 Testing Growth | - | - | - | -39.32% | -59.41% | -89.75% | - |
| Service | 184.54M | 368.01M | 409.67M | 569.94M | 743.24M | - | - |
| Service Growth | - | 99.42% | 11.32% | 39.12% | 30.41% | - | - |
| Product | 254.43M | 404.33M | 365.47M | 438.65M | 545.46M | - | - |
| Product Growth | - | 58.92% | -9.61% | 20.02% | 24.35% | - | - |
| Product and Service, Other | - | 37.78M | 39.92M | 53.72M | 136.01M | - | - |
| Product and Service, Other Growth | - | - | 5.67% | 34.55% | 153.19% | - | - |
| International Sales | - | 11.44M | 77.48M | 109.91M | 117.74M | - | - |
| International Sales Growth | - | - | 577.07% | 41.85% | 7.12% | - | - |
| Product And Service Other | 15.49M | - | - | - | - | - | - |
| Product And Service Other Growth | - | - | - | - | - | - | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| UNITED STATES | - | 864.85M | 1.41B | 1.66B | 1.97B | 2.35B | 2.57B |
| UNITED STATES Growth | - | - | 63.49% | 17.21% | 18.67% | 19.32% | 9.52% |
| Non-US | - | 11.44M | 77.48M | 109.91M | 117.74M | 153.28M | 189.09M |
| Non-US Growth | - | - | 577.07% | 41.85% | 7.12% | 30.18% | 23.37% |
Exact Sciences Corporation (EXAS) reported $3.08B in revenue for fiscal year 2024. This represents a 73934% increase from $4.2M in 2011.
Exact Sciences Corporation (EXAS) grew revenue by 10.4% over the past year. This is steady growth.
Exact Sciences Corporation (EXAS) reported a net loss of $986.6M for fiscal year 2024.
Exact Sciences Corporation (EXAS) has a return on equity (ROE) of -37.1%. Negative ROE indicates the company is unprofitable.
Exact Sciences Corporation (EXAS) generated $247.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.